Senvelgo: risk of ketoacid diabetes associated with the use of the veterinary medicine
SENVELGO® (velagliflozin) 15 mg/ml - oral solution for cats - has been granted a marketing authorisation by the European Commission in November 2023. At the request of the European Medicines Agency and, for France, the National agency for veterinary medicinal products, Boehringer Ingelheim Vetmedica GmbH disseminates information on the occurrence of serious adverse reactions and how to prevent them.
Serious adverse reactions, including ketoacid diabetes and deaths, have been reported via the European Veterinary Pharmacovigilance Network since the marketing of SENVELGO®. In a letter to veterinarians, Boehringer Ingelheim Vetmedica GmbH mentions several important information for the safe use of this medicine.
For more information on the implementation of sthis communication action